If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Interesting.
Hopefully Hemo can still play a part in CV-19 treatment /testing.
If they find an antibody too and develop a treatment quickly, perhaps US & UK will use their treatment, China & Asia will use harbour biomeds
from 15th March 2018
"Destiny Pharma has been granted fast-track designation by the US drug regulator for its lead clinical candidate. (XF-73) has been granted the designation by the Food and Drug Administration (FDA) for its development as a means of prevention of post-surgical infections such as methicillin resistant staphylococcus aureus (MRSA)."
Hi all I've just found this company and decided it looks like good value to buy at the moment so purchased a small amount of shares.
Love what the company are aiming to do because anit-microbial resistance (AMR) will likely be a serious issue for us in the future.
"Company funded through to Q4 2021"
If you are struggling to see the link between Hemo and J&J then you haven't researched the company enough to make an investment decision:
https://hemogenyx.com/wp-content/uploads/2018/10/Hemogenyx-Pharma-Plc-Collaboration-with-Johnson-Johnson-Innovation.pdf
Specifically for this case see the following from the article @InvestNI:
"Companies submitting assets to the effort will retain the IP they own, allowing it to be licensed in subsequent partnerships."
I agree companies need to be rewarded both socially and financially for their fantastically difficult work in eradicating disease for all of us.
It's great to see companies come together like this it's a brilliant collaborative atmosphere; however we cannot expect scientists to do the extremely difficult work they do for free.
hTTps://www.biocentury.com/article/304928/biocentury-is-providing-this-story-for-free-given-the-urgent-need-for-information-about-the-covid-19-crisis-for-more-analysis-sign-up-for-our-daily-email
GSK could be Hemogenyx secret partner for CDX
“By further optimizing these antibodies we should be able to create an effective therapy for infected patients or even to prevent illness in those at risk for developing the infection,” Barron said.
"One consideration is whether a compound can be rapidly scaled for manufacturing. Without that capability, the potential short-term utility would be low, meaning such compounds would be unlikely to make the first wave."
"Barron (of GSK) is running the group that is evaluating novel antibody opportunities"
"Specifically, Barron said the team is looking for clues to how the body generates neutralizing antibodies by studying patients who have been infected with coronavirus and successfully recovered."